Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Income from Continuing Operations of 19763000.0 for Q1 2026, up 289.96% year-over-year from 5068000.0 in Q1 2025, and down 15.65% quarter-over-quarter from 23431000.0 in Q4 2025.
Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Tg Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 19763000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 289.96% year-over-year to 19763000.0; the TTM figure through Mar 2026 stood at 462276000.0 (up 879.92% YoY), while the FY2025 annual figure was 447528000.0, up 1323.44% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19763000.0, down from 23431000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 390895000.0 in Q3 2025, with the low at 75655000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 3868000.0 (2024), against an average of 15560294.12.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 96.6% in 2024, then surged 10005.87% in 2025.
- Tg Therapeutics' Income from Continuing Operations stood at 75655000.0 in 2022, then soared by 82.39% to 13326000.0 in 2023, then jumped by 335.54% to 31388000.0 in 2024, then retreated by 25.35% to 23431000.0 in 2025, then dropped by 15.65% to 19763000.0 in 2026.
- Business Quant data shows TGTX's Income from Continuing Operations at 19763000.0 in Q1 2026, 23431000.0 in Q4 2025, and 390895000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73 Mn |
| Mar 31, 2026 | 19.76 Mn |
| Dec 31, 2025 | 23.43 Mn |
| Sep 30, 2025 | 390.90 Mn |
| Jun 30, 2025 | 28.19 Mn |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 31.39 Mn |
| Sep 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 6.85 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -13.33 Mn |
| Sep 30, 2023 | 113.93 Mn |
| Jun 30, 2023 | -47.61 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -75.66 Mn |
| Sep 30, 2022 | -40.96 Mn |
| Jun 30, 2022 | -56.23 Mn |
| Mar 31, 2022 | -75.13 Mn |
| Dec 31, 2021 | -95.89 Mn |
| Sep 30, 2021 | -103.17 Mn |